Scarica l'app Stockscreener
2.48
5.98%
0.14
Dopo l'orario di chiusura:
2.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.34
Aprire:
$2.46
Volume 24 ore:
15.40M
Relative Volume:
2.51
Capitalizzazione di mercato:
$813.19M
Reddito:
$4.41M
Utile/perdita netta:
$-67.85M
Rapporto P/E:
-10.98
EPS:
-0.2258
Flusso di cassa netto:
$-57.15M
1 W Prestazione:
+54.04%
1M Prestazione:
+75.89%
6M Prestazione:
+131.78%
1 anno Prestazione:
+357.14%
Intervallo 1D:
$2.405
$2.67
Intervallo di 1 settimana:
$1.54
$2.67
Portata 52W:
$0.515
$2.67
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
2.48 | 813.19M | 4.41M | -67.85M | -57.15M | -0.2258 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | Oppenheimer | Outperform |
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen (OCGN) Is Up 54.0% After Completing Phase 3 OCU400 Enrollment And Facing Going-Concern Warning - simplywall.st
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight - Yahoo Finance
Analyst Confidence Sparks Surge in Ocugen Shares - AD HOC NEWS
Ocugen Stock Jumps as Oppenheimer Initiates Outperform Rating - StocksToTrade
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
Ocugen Stock Surges Amid Positive Analyst Coverage and Clinical Progress - StocksToTrade
Ocugen Stock Surges Amid Oppenheimer’s Bullish Forecast - timothysykes.com
Ocugen, Inc. (NASDAQ: OCGN) Q4 2025 earnings call transcript - MSN
Ocugen Stock Soars Following Strategic Developments in Gene Therapy Trials - timothysykes.com
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - AOL.com
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story - Yahoo Finance
Ocugen (OCGN) Valuation Update As Phase 3 OCU400 Enrollment Completes And Going Concern Risks Persist - simplywall.st
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Ocugen (OCGN) Surges to 52-Week High on Oppenheimer's Outperform Rating - GuruFocus
Investors Buy Large Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen stock wins new Outperform at Oppenheimer (OCGN:NASDAQ) - Seeking Alpha
Ocugen (NASDAQ:OCGN) Hits New 12-Month HighWhat's Next? - MarketBeat
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline - AOL.com
OCGN: Oppenheimer Initiates Coverage with Outperform Rating | OC - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for Ocugen - MarketBeat
Oppenheimer Initiates Ocugen at Outperform With $10 Price Target - marketscreener.com
Oppenheimer initiates Ocugen stock rating at Outperform on gene therapy potential - Investing.com
Ocugen price target raised to $22 from $15 at Lucid Capital - TipRanks
Oppenheimer initiates coverage of Ocugen (OCGN) with outperform recommendation - MSN
Ocugen's Clinical Ambition Meets Market Skepticism - AD HOC NEWS
Ocugen’s Gene Therapy Pipeline Dominates Earnings Call - TipRanks
Ocugen Faces Analyst Scrutiny Despite Pipeline Progress - AD HOC NEWS
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline - MyChesCo
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo! Finance Canada
FY2030 Earnings Forecast for Ocugen Issued By HC Wainwright - MarketBeat
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy - MyChesCo
Ocugen: Downgrade "Hold" After OCU410 Data Release (NASDAQ:OCGN) - Seeking Alpha
312,319,623 Common Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Ocugen, Inc. honors women leaders advancing gene therapy innovation - Traders Union
Is Ocugen Inc. (2H51) stock worth buying before Fed actionInsider Selling & Free High Return Stock Watch Alerts - Naître et grandir
Will Ocugen Inc. stock continue upward momentumTrade Exit Report & AI Optimized Trade Strategies - Naître et grandir
Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value - The Globe and Mail
Ocugen (NASDAQ:OCGN) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Employee dedication drives gene therapy progress, Ocugen, Inc. asserts - Traders Union
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Trading Down 7.2%Here's Why - MarketBeat
OCGN Analyst Rating Maintained by Chardan Capital at Buy with $7 - GuruFocus
Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Ocugen, Inc. Hits New 52-Week High of $2.00, Marking Major Milestone - Markets Mojo
Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com South Africa
Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):